ArticleFrontiers in pediatrics2026
Case Report: Vincristine extravasation managed with amniotic membrane graft in a pediatric patient with Wilms tumor.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vincristine is a commonly used chemotherapeutic agent in pediatric oncology and, because of its vesicant properties, may cause severe tissue injury in cases of extravasation. We present a pediatric case in which tissue damage developing after vincristine extravasation during treatment for Wilms tumor was managed with an amniotic membrane graft following clinical progression despite standard conservative measures. A 2 year eight month old boy developed vincristine extravasation from a peripheral intravenous line on the dorsolateral aspect of the left foot during week 24 of carboplatin-vincristine chemotherapy for Stage II Wilms tumor. The progression of tissue injury despite initial conservative management suggested that amniotic membrane grafting may represent a useful alternative therapeutic option, especially in extravasation injuries involving functionally critical regions that do not respond adequately to conventional approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.